LONG MINI-FUTURE - GENMAB | Market Closed - Boerse Frankfurt Warrants 19:01:51 24/06/2024 BST | ||
| 3.04 EUR | -3.49% |
|
| Current month | -39.92% | ||
| 1 month | -41.54% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
| Date | Price | Change |
|---|---|---|
| 24/06/24 | 3.04 | -3.49% |
| 20/06/24 | 3.15 | +14.13% |
| 19/06/24 | 2.76 | -8.31% |
| 18/06/24 | 3.01 | -4.75% |
| 17/06/24 | 3.16 | -10.48% |
Real-time Boerse Frankfurt Warrants
Last update June 24, 2024 at 07:01 pm
More quotesStatic data
| Product type | Knock-Out mit Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | GENMAB A/S |
| Issuer | 
Vontobel
|
| WKN | VP13K0 |
| ISIN | DE000VP13K09 |
| Date issued | 31/03/2020 |
| Strike | 1,554 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.72 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 25.85 € |
|---|---|
| Lowest since issue | 0.69 € |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,805
DKK
Average target price
2,464
DKK
Spread / Average Target
+36.51%
- Stock Market
- Certificates
- Certificat
